Novo Nordisk affected by pricing pressure in the US
Victoza is performing well on the crucial American market, while growth for other products is low. CEO Lars Rebien Sørensen points to increased pressure on prices as the reason, adding that recent events will ensure that the trend continues.
BY STEFAN SINGH KAILAY
Things are looking up for Victoza on the US market, while the rest of Novo Nordisk’s diabetes franchise has trouble keeping up with the flagship product. That was the main conclusion from last week’s financial report for the first six months of the year from the Danish-based drug group.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Rebien: We could do better in China
For abonnenter
Novo’s Victoza left out of Express list once again
For abonnenter
